PremiumCompany AnnouncementsPacira’s Earnings Call Highlights Strategic Wins and Growth Pacira BioSciences Reports Q1 2025 Financial Results Pacira reports Q1 EPS 65c, consensus 60c PremiumPre-EarningsPCRX Earnings this Week: How Will it Perform? Pacira BioSciences authorizes $300M share repurchase program Pacira reports inducement grants under Nasdaq listing rule PremiumThe FlyClosing Bell Movers: Levi Strauss up 8% on earnings, futures find footing Pacira Pharmaceuticals Settles Patent Litigation with Fresenius Pacira announces settlement of U.S. patent litigation for Exparel 
